# CCR8 Antagonist Nanobody Design
WT CCR8 targeting CRS2.5 pocket blocking nanobody design for cancer immunotherapy.

**Project**: Envafolimab-based antagonist nanobody targeting CCR8 CRS2.5 site

**Target**: Wild-type CCR8 (UniProt P51685) - 355 aa GPCR
**Strategy**: Block CCL1 two-step binding via CRS2.5 pocket penetration
**Framework**: Envafolimab (clinically proven) + CDR engineering

**Status**: Phase 2 - WT CCR8 redesign (2026-01-28)\n
